Jump to content

Available Clinical Trial: ES-SCLC


Recommended Posts

ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide)
More info here: https://www.lungevity.org/for-patients-caregivers/navigating-your-diagnosis/participate-in-research/featured-clinical-trials

Marshika Vickers
Phone Number: 510-473-2872
Email: marshika_vickers@henlius.com

ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This is a study to learn the effects of the study drug plus chemotherapy on ES-SCLC, compared with atezolizumab combined with chemotherapy. Atezolizumab combined with chemotherapy (etoposide + carboplatin) was approved by the Food and Drug Administration (FDA) in March 2019 in the treatment of ES-SCLC.

Who can participate?

This study is for adults who:

Are 18 years of age and older
Have been diagnosed with ES-SCLC
Have NOT already received treatment for ES-SCLC
Note: If you have received chemotherapy for limited-stage SCLC, it must have taken place more than 6 months before starting this study.
Other criteria also apply.


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.